ReviR Therapeutics
PrivateLast Round
Grant
Nov 20, 2025
Total Funding Raised
$54.6M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
ReviR Therapeutics is a biotechnology company that develops AI-driven RNA-targeting small molecule therapies to treat cancer, rare genetic disorders, and infectious diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Infrastructure
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
ReviR Therapeutics Comparables
Compare ReviR Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ribometrix | 92% | |
| Wayfinder Biosciences | 91% | |
| Arrakis Therapeutics | 89% |
ReviR Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Nov 20, 2025 | ||||
| Series A | Jul 26, 2024 | ||||
| Seed | Jan 17, 2022 |
ReviR Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| CDH Investments | Series A, Seed |
| Yael Capital | Series A |
| Tiantu Capital | Seed |
| Lapam Capital | Series A |
| Sky9 Capital | Seed |
| 5Y Capital | Series A, Seed |
| California Institute for Regenerative Medicine | Grant |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 57% MoM, reaching 5,000.
- Jul 26, 2026
Monthly visitors increased 63% MoM.
Recent news
Latest coverage and updates
- is_developingAug 27, 2026
Revir Therapeutics is developing RTX-117 on Aug 27th '26.
- recognized_asAug 27, 2026
Revir Therapeutics recognized as rare paediatric disease designation.
ReviR Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about ReviR Therapeutics's valuation, stock price, and market status.
Is ReviR Therapeutics a public or private company?
ReviR Therapeutics is a private company.
What is the current stock price of ReviR Therapeutics?
ReviR Therapeutics is a private company with no public stock price. No recent secondary market data is available.
How much is ReviR Therapeutics worth (valuation)?
Valuation information for ReviR Therapeutics is not publicly available.
Can I buy ReviR Therapeutics stock?
ReviR Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was ReviR Therapeutics's last funding round?
ReviR Therapeutics's most recent funding round was Grant on November 20, 2025.
Who are the main investors in ReviR Therapeutics?
Key investors in ReviR Therapeutics include CDH Investments, Lapam Capital, 5Y Capital, California Institute for Regenerative Medicine (CIRM).
Will ReviR Therapeutics IPO soon?
No public IPO plans have been announced for ReviR Therapeutics.
How can I track ReviR Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor ReviR Therapeutics's secondary market activity and sign up for updates.